Media headlines about Covance (NYSE:CVD) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Covance earned a coverage optimism score of 0.06 on Accern’s scale. Accern also assigned news coverage about the healthcare company an impact score of 45.4614201135402 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Covance (CVD) Stock Price” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/09/15/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-covance-cvd-stock-price.html.

Covance Company Profile

Covance Inc is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services.

Insider Buying and Selling by Quarter for Covance (NYSE:CVD)

Receive News & Ratings for Covance Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covance Inc. and related companies with MarketBeat.com's FREE daily email newsletter.